CORE-018: PROTOCOL REVIEW AND MONITORING SYSTEM (PRMS) PROJECT SUMMARY / ABSTRACT The Protocol Review and Monitoring System [PRMS] of the OSUCCC consists of a Clinical Scientific Review Committee [CSRC] that reviews all new cancer-related clinical protocols for scientific merit prior to IRB submission and monitors the scientific progress of ongoing studies including accrual rates. The main CSRC is organized into two teams (with highly similar composition) that collectively meet twice monthly (each once per month), facilitating rapid protocol review. The CSRC consists of 37 members representative of all the OSUCCC research programs and includes clinical and basic researchers, biostatisticians, pharmacists, and research nurses. Additionally, members with specific expertise in the areas of cancer prevention and control as well as pediatrics are convened as CSRC sub-committees to provide focused review of these protocols. At its twice monthly meetings, the main CSRC performs full scientific reviews of all cancer-related clinical protocols initiated by local investigators or pharmaceutical industry sponsors and acknowledges NIH peer-reviewed studies. Each CSRC member is expected to be present at each scheduled meeting, and a majority of the voting members scheduled to be at a meeting must be present to attain a quorum for the meeting. Failure to achieve a quorum at a meeting precludes any business being conducted. In addition to achieving quorum, appropriate reviewer expertise must be present in order for business to be conducted. CSRC approval of a protocol is required prior to its review by the OSU Cancer Institutional Review Board. Each protocol is reviewed by four CSRC members (a primary reviewer, a secondary reviewer, a biostatistician, and a pharmacist). Reviewers follow a written review template that calls for an analysis of the scientific hypothesis and rationale, experimental design, patient inclusion and exclusion criteria, treatment plan, statistical plan, pharmacy considerations and proper prioritization. As of January 2009, all new research protocols undergo concurrent review by the CSRC Logistics Review Committee (LRC), which is a sub-committee of the CSRC. The LRC was implemented to facilitate trial activation and confirm proper research prioritization. The LRC does not evaluate the scientific aspects of the protocol, but does evaluate the availability of the resources necessary to successfully implement and complete the research protocol. The CSRC Executive Committee (EC) provides oversight to the CSRC. It is led by the CSRC Chair. The EC consists of eight CSRC members that meet monthly to review protocol accrual and scientific progress and ensure that protocol prioritization rules are followed. The CSRC EC is responsible for communication with investigators whose clincial trials are not meeting their accrual goals and providing support to facilitate accrual. The CSRC adheres to a set of well- defined criteria for accrual monitoring and trial prioritization. Those ongoing studies that do not show adequate accrual or fail to meet accepted standards of quality control based on formal audits are terminated. In 2014, the CSRC closed 18 trials for low accrual. The EC also performs expedited reviews for appropriate studies (e.g., retrospective studies). In the last year (12/1/13 to 11/30/14), 199 new protocols were reviewed by the CSRC with the following dispositions: 68 (34%) were approved as written, 55 (28%) were approved with stipulations, 14 (7%) were deferred, 57 (29%) were administratively acknowledged after having undergone previous NIH peer-review, and 5 (2%) were disapproved. Twenty-eight non-interventional protocols were also administratively approved by the CSRC EC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-44
Application #
9843879
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Reeves, Katherine W; Pennell, Michael; Foraker, Randi E et al. (2018) Predictors of vasomotor symptoms among breast cancer survivors. J Cancer Surviv 12:379-387

Showing the most recent 10 out of 2602 publications